Sentiment Survey
|
|
|
|
|
|
|
|
|
|
|
|
Investment Grade:
|
|
Comments(0)
|
(0)
|
(0)
|
Ranking History
Headlines
- EpiCept Reports New Data on Benefits of Maintenance Therapy With Ceplene® and interleukin-2 For AML Patients At ASH Annual Meeting
Dec 04, 2008 12:02 AM
- Epicept Corporation to Present at the NYSSA 12th Annual Biotech and Specialty Pharma Conference
Nov 26, 2008 04:02 PM
- EpiCept Corporation Reports Third Quarter 2008 Operating and Financial Results
Nov 07, 2008 12:02 AM
- EpiCept to Report Third Quarter 2008 Operating and Financial Results on November 7, 2008
Nov 05, 2008 04:46 PM
- EpiCept Corporation to Present at Two Upcoming Investor Conferences
Oct 27, 2008 12:02 AM
- EpiCept Receives Ceplene(R) Marketing Approval in Europe
Oct 09, 2008 12:02 AM
- EpiCept Amends DURECT Bupivacaine Patch Licensing Agreement
Sep 15, 2008 12:02 AM
- EpiCept Regains Compliance with Nasdaq Listing Rule
Aug 27, 2008 09:00 PM
- EpiCept Announces Pricing of Public Offering
Aug 11, 2008 11:46 PM
- EpiCept Corporation Reports Second Quarter 2008 Operating and Financial Results
Aug 11, 2008 12:02 AM
- Form 5 Caspritz Gert For: Dec 31 (10K)
Oct 08, 2008 01:22 PM
- Form 4 EPICEPT CORP For: Sep 08 Filed by: Wiedemann Oliver (10K)
Sep 10, 2008 04:53 PM
- Form 4 EPICEPT CORP For: Sep 08 Filed by: Tseng Ben (10K)
Sep 10, 2008 04:53 PM
- Form 4 EPICEPT CORP For: Sep 08 Filed by: Talley John V. (10K)
Sep 10, 2008 04:49 PM
- Form 4 EPICEPT CORP For: Sep 08 Filed by: Cook Robert W. (10K)
Sep 10, 2008 04:46 PM
- Form 4 EPICEPT CORP For: Sep 08 Filed by: BHAGWAT DILEEP (10K)
Sep 10, 2008 04:46 PM
- Form 4 EPICEPT CORP For: Sep 08 Filed by: ALLARD STEPHANE (10K)
Sep 10, 2008 04:43 PM
- Form 4 Yetter Wayne P. For: Jun 30 (10K)
Jul 02, 2008 10:20 AM
- Form 4 Waldheim Gerhard For: Jun 30 (10K)
Jul 02, 2008 10:18 AM
- Form 4 Savage Robert G. For: Jun 30 (10K)
Jul 02, 2008 10:17 AM
Analyst Ratings
|
|
Share Performance
|
Period
|
EPCT
|
Compare to S&P
|
| YTD |
-51.18 %
|
-0.01 %
|
| 4 Weeks |
-16.22 %
|
-8.32 %
|
| 12 Weeks |
1.64 %
|
43.81 %
|
|
Financial Ratios
Earnings Performance
|
EPS Growth in Last Quarter: 40.00 %
|
|
EPS Growth in Last Year: 55.00 %
|
|
Sales Growth in Last Quarter: 85.71 %
|
|
Sales Growth in Last Quarter: 69.57 %
|
|
|
